The use of imaging in the early development of neuropharmacological drugs: A survey of approved NDAs

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 1, 2008, Pages 69-74

  Uppoor, R S ^a   Mummaneni, P ^a   Cooper, E ^b   Pien, H H ^b   Sorensen, A G ^b   Collins, J ^a,c   Mehta, M U ^a   Yasuda, S U ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUORO 3 [3 [4 (5 METHOXY 4 PYRIMIDINYL) 1 PIPERAZINYL]PROPYL] 1H INDOLE; ANTIDEPRESSANT AGENT; APREPITANT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; ELETRIPTAN; GADOLINIUM; ICI 214227; M 236303; MITOXANTRONE; NEUROLEPTIC AGENT; NEW DRUG; PAROXETINE; QUETIAPINE; RACLOPRIDE C 11; TRIPTAN DERIVATIVE; ZIPRASIDONE; ZONISAMIDE;

BIPOLAR DISORDER; CAUDATE NUCLEUS; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG LABELING; DRUG SAFETY; ECHOGRAPHY; EPILEPSY; FOCAL EPILEPSY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMAGING SYSTEM; MAJOR DEPRESSION; MANIA; MIGRAINE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROPHARMACOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SOMNOLENCE;

DATA COLLECTION; DIAGNOSTIC IMAGING; DRUGS, INVESTIGATIONAL; INVESTIGATIONAL NEW DRUG APPLICATION; NEUROPHARMACOLOGY; TIME FACTORS;

EID: 45549085290     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100422     Document Type: Review

References (12)

1. Gefvert, O., Bergstrom, M., Langstrom, B., Lundberg, T., Lindstrom, L. & Yates, R. Time course of central nervous system dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl.) 135, 119-126 (1998).
2. 11C]raclopride. Neuropharmacology 27, 248-259 (2002).
3. Mamo, D. et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am. J. Psychiatry 161, 818-825 (2004).
4. Novantrone [prescribing information]. Rockland, MA: Serono, 2005.
5. Zonegran [package insert]. Teaneck, NJ: Eisai, 2004.
6. Relpax [prescribing information]. New York, NY: Pfizer Roerig, 2006.
7. Pien, H.H., Fischman, A.J., Thrall, J.H. & Sorensen, A.G. Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discov. Today 10, 259-266 (2005).
8. Keller, M. et al. Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psych. 59, 216-223 (2005).
9. Christian, B.T. et al. Evaluation of cerebral pharmacokinetics of the novel antidepressant drug BMS-181101, by positron emission tomography. J. Pharmacol. Exp. Ther. 279, 325-331 (1996).
10. Salazar, D.E. & Fischman, A.J. Central nervous system pharmacokinetics of psychiatric drugs. J. Clin. Pharmacol. 39, 10S-12S (1999).
11. Lee, C.-M., & Farde, L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol. Sci. 27, 310-317 (2006).
12. van Waarde, A. Measuring receptor occupancy with PET. Curr. Pharm. Des. 6, 1593-1610 (2000).